Publications

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Cancer immunology, immunotherapy : CII

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

01-09-2016

European journal of cancer (Oxford, England : 1990)

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

01-09-2016

World journal of urology

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

01-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

15-06-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Cancer immunology, immunotherapy : CII

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

01-05-2016

Science (New York, N.Y.)

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

09-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

The Lancet. Oncology

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

01-08-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

International immunology

Therapeutic use of anti-CTLA-4 antibodies.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

01-04-2014